Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
9.9
3.4
Journals
Vaccines
Special Issues
The Development of Peptide-Based Vaccines
share announcement

The Development of Peptide-Based Vaccines

A special issue of Vaccines (ISSN 2076-393X).

Deadline for manuscript submissions: 31 October 2025 | Viewed by 766

Special Issue Editors

Dr. José Manuel Pérez De La Lastra

E-Mail Website
Guest Editor
Biotechnology of Macromolcules, Instituto de Productos Naturales y Agrobiología, CSIC, 28006 Madrid, Spain
Interests: biotechnology; macromolecules; antimicrobials; IgY antibodies; peptides; epitopes
Special Issues, Collections and Topics in MDPI journals
Prof. Dr. José de la Fuente

E-Mail Website
Guest Editor
1. SaBio, IREC (CSIC-UCLM-JCCM), Ciudad Real, Spain
2. Department of Veterinary Pathobiology, CVHS, Oklahoma State University, Stillwater, OK, USA
Interests: infectious diseases; molecular biology of host-vector-pathogen interactions; gene regulation; pathogenesis; functional genomics; evolution and immunology; systems biology; ticks and tick-borne diseases; intracellular bacteria (Rickettsia, Anaplasma, Mycobacterium); vaccinology; biotechnology
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

This Special Issue covers a wide range of topics, including the design and synthesis of peptide antigens, strategies to enhance immunogenicity, and innovative delivery systems. We invite contributions that go beyond predicted outcomes, specifically focusing on experimental evidence demonstrating that immunogens are immunogenic and elicit an appropriate immune response. Papers addressing the molecular mechanisms underlying the efficacy of peptide vaccines, the role of adjuvants, and the challenges of translating preclinical findings into clinical applications are particularly welcome.

This Special Issue will also highlight the emerging use of peptide vaccines in combating infectious diseases, cancer, and autoimmune diseases. Special attention will be given to novel approaches such as multi-epitope and personalized peptide vaccines, as well as the integration of computational tools in peptide vaccine development. This Special Issue aims to bring together researchers from diverse fields to foster interdisciplinary collaboration and provide a platform for the exchange of cutting-edge research that demonstrates real-world efficacy, paving the way for the next generation of peptide vaccines.

Dr. José Manuel Pérez De La Lastra
Prof. Dr. José de la Fuente
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • peptide antigens
  • vaccine design
  • immunogenicity
  • epitope mapping
  • adjuvants
  • multi-epitope vaccines
  • personalized peptide vaccines
  • vaccine delivery systems
  • computational vaccine design
  • synthetic peptides

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Other

10 pages, 1220 KB  
Case Report
Case Report: A Multi-Peptide Vaccine Targeting Individual Somatic Mutations Induces Tumor Infiltration of Neoantigen-Specific T Cells in a Patient with Metastatic Colorectal Cancer
by Armin Rabsteyn, Henning Zelba, Borong Shao, Lisa Oenning, Christina Kyzirakos, Simone Kayser, Tabea Riedlinger, Johannes Harter, Magdalena Feldhahn, Dirk Hadaschik, Florian Battke, Veit Scheble, Alfred Königsrainer and Saskia Biskup
Vaccines 2025, 13(9), 960; https://doi.org/10.3390/vaccines13090960 - 11 Sep 2025
Viewed by 369
Abstract
Background/Objectives: Fully personalized peptide vaccines targeting tumor-specific mutations are a promising treatment option for patients in an adjuvant but also advanced/metastatic disease situation in addition to non-personalized standard therapies. Here, we report a patient’s case with advanced metastatic colorectal cancer (mCRC) who was [...] Read more.
Background/Objectives: Fully personalized peptide vaccines targeting tumor-specific mutations are a promising treatment option for patients in an adjuvant but also advanced/metastatic disease situation in addition to non-personalized standard therapies. Here, we report a patient’s case with advanced metastatic colorectal cancer (mCRC) who was treated with a neoantigen-derived multi-peptide vaccine in addition to standard of care. Methods: Tumor-specific mutations were identified by whole exome and transcriptome sequencing. An individualized peptide vaccine was designed using an in-house developed epitope prediction and vaccine design platform. In this case, the vaccine consisted of 20 peptides targeting 18 distinct mutations. The vaccine was administered according to a prime-boost scheme for a total of 12 vaccinations. Vaccine immunogenicity was determined by stimulation of patient T cells with vaccinated peptides and subsequent intracellular cytokine staining (ICS). Tumor-infiltrating lymphocytes (TIL) were analyzed by ICS and T cell receptor beta chain (TCRβ) sequencing. Results: The patient survived for 41 months since initial diagnosis despite continuous disease progression under all therapeutic interventions. The vaccination induced multiple neoantigen-specific T cell responses in the patient without notable side effects. Two liver metastases were resected five months after the start of vaccination, and TIL were extracted and cultured. Analysis of TIL cultures revealed tumor infiltration by vaccine-induced neoantigen-specific T cells in only one of the metastases. TCRβ sequencing of neoantigen-specific T cells and tumor tissues supported this finding. Vaccine-targeted variants were reduced or absent in the metastasis with vaccine-specific T cell infiltration. Conclusions: This case demonstrates immunogenicity of a neoantigen-derived peptide vaccine and highlights tumor-infiltrating capabilities and potential cytotoxicity of vaccine-induced T cells in mCRC. Full article
(This article belongs to the Special Issue The Development of Peptide-Based Vaccines)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop